Chiesi Farmaceutici S.p.A. et al v. Teva Pharmaceuticals Inc. et al
| Chiesi Farmaceutici S.p.A. and Amryt Endo, Inc. |
| Teva Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. |
| 1:2024cv00441 |
| April 8, 2024 |
| U.S. District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on May 30, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 10 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals Inc. filed by Teva Pharmaceuticals Inc.. (Keller, Karen) |
| Filing 9 STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to July 12, 2024 - filed by Teva Pharmaceuticals Inc.. (Keller, Karen) |
SO ORDERED, re #9 STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to July 12, 2024, filed by Teva Pharmaceuticals Inc. Reset Answer Deadlines: Teva Pharmaceuticals Inc. answer due 7/12/2024. Ordered by Judge Colm F. Connolly on 5/30/2024. (kmd)
|
| Filing 8 SUMMONS Returned Executed by Chiesi Farmaceutici S.p.A., Amryt Endo, Inc..Teva Pharmaceuticals Inc. served on 5/13/2024, answer due 6/3/2024. (Farnan, Kelly) |
| CORRECTING ENTRY: The Amended Complaint at D.I. #7 has been replaced per counsel's request. (kmd) |
| Filing 7 AMENDED COMPLAINT against All Defendants - filed by Chiesi Farmaceutici S.p.A., Amryt Endo, Inc.. (Attachments: #1 Patent/Trademark Report, #2 ANDA Form, #3 Exhibit A - 198 Patent, #4 Exhibit B - 695 Patent, #5 Exhibit C - 812 Patent, #6 Exhibit D - 246 Patent, #7 Exhibit E - 709 Patent, #8 Exhibit F - 397 Patent, #9 Exhibit G - 126 Patent, #10 Exhibit H - 457 Patent, #11 Exhibit I - 011 Patent, #12 Exhibit J - 963 Patent, #13 Exhibit K - 595 Patent, #14 Exhibit L - 316 Patent, #15 Exhibit M - 471 Patent)(Farnan, Kelly) (Main Document 7 replaced on 5/2/2024) (kmd). |
| Filing 6 STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Valline S.r.l. for Chiesi Farmaceutici S.p.A.; Corporate Parent Chiesi Farmaceutici S.p.A., Corporate Parent Amryt Pharmaceuticals Inc., Corporate Parent Amryt Pharma Holdings Limited, Corporate Parent Amryt Pharma Limited for Amryt Endo, Inc. filed by Amryt Endo, Inc., Chiesi Farmaceutici S.p.A. (apk) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s)(SEE PATENT REPORT) (apk) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/27/2024. Date of Expiration of Patent: SEE ANDA FORM.Thirty Month Stay Deadline: 8/27/2026. (apk) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Inc. ( Filing fee $ 405, receipt number ADEDC-4380063.) - filed by Chiesi Farmaceutici S.p.A., Amryt Endo, Inc. (Attachments: #1 Exhibit A-L, #2 Civil Cover Sheet)(apk) |
| No Summons Issued. (apk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
